Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn pyrrolidone carboxylic acid
learn D-Pantothenyl Alcohol
learn panthenyl ethyl ether
Research
5 / 1000+ results
research Effect of hair restoration surgery on the scalp sensitivity
Hair transplant surgery reduces scalp sensitivity by almost 40%, and smokers have less scalp sensitivity than non-smokers. The time since surgery doesn't significantly affect this.
research Skin disorders in Parkinson’s disease: potential biomarkers and risk factors
Certain skin conditions may indicate or increase the risk of Parkinson's disease.
research Atroposelective Synthesis of Biaryl N‐Oxides via Cu‐Catalyzed De Novo Heteroaromatic N‐Oxide Ring Formation
A new method efficiently creates biaryl N-oxides with potential for cancer treatment and drug development.
research RARE CASE OF OVARIAN STEROID CELL TUMOR NOT OTHERWISE SPECIFIED IN A POSTMENOPAUSAL WOMAN
A woman's rare ovarian tumor was treated with surgery, which stopped her symptoms and normalized her hormone levels.
research Cystoid macular oedema in uveitis: An unsolved problem
Treating cystoid macular oedema in uveitis is difficult and risky.
Community Join
5 / 1000+ resultscommunity Topical Spironolactone 2.5% MONOTHERAPY x 5 months (MALE)- Nothing else
A man in his 40s treating his slow balding with a daily regimen of 2.5% spironolactone topical solution and Piroctone Olamine Shampoo. Despite initial hair shedding, he experienced no side effects and plans to continue the treatment for at least a year.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Oral PTD-DBM available online, worth giving a shot?
Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.